A recent review, however, evaluated 16 studies of anti-VEGF therapy for CNV secondary to non-age-related macular degeneration conditions and concluded that positive treatment outcomes in these patients should encourage clinicians to consider bevacizumab and ranibizumab for rare causes of CNV [14]. This evidence concerns the gene VEGFA and age-related macular degeneration.